– The research also found that the vaccine induced a similar immune response to that found among adults
– The data was released as a fresh cluster of cases in primary school children has intensified the debate about vaccinating under-12s
LONDON – Interim analysis of Phase 3 clinical trial of the CoronaVac vaccine in more than 10,000 participants in Turkey suggests the efficacy of two doses of the vaccine is 83.5 percent against symptomatic cases of COVID-19, according to a study published on Thursday in The Lancet, a weekly peer-reviewed general medical journal.
– Chinese company says initial studies indicate that CoronaVac induced antibodies in more than 96 per cent of trial participants
– Immune responses among children and teenagers were higher than adults assessed in previous studies, researchers say
In an editorial published on Saturday, medical journal The Lancet reviewed China’s COVID-19 response strategy and discussed how China has managed to control the epidemic and what lessons the global scientific community can learn from China’s experiences.
Only 2.7 percent of people in Wuhan, Hubei province have neutralizing antibodies against the novel coronavirus, which means the public generally lacks immunity. Therefore, strong measures should be taken to prevent a domestic recurrence of the pandemic, a paper published in The Lancet said on Friday.
Responding to the military coup of Feb 1, 2021, the citizens of Myanmar are on the airwaves, the web, and the streets peacefully protesting their outrage and unreserved rejection of this unlawful and anti-democratic act. Emergency Medicine (EM) doctors have led the resistance through a Civil Disobedience Movement (CDM), minimising work in government hospitals under military rule. The CDM has spread throughout the health workforce, resulting in closure of public hospitals as well as medical and nursing universities. Clinical services have drastically diminished, leading to a health system suddenly in crisis.
Une étude chinoise à Wuhan rapporte que, six mois après avoir été infectés par le Covid-19, 76 % des patients hospitalisés souffrent encore de symptômes liés au virus.
An unprecedented pandemic, COVID-19 is currently hitting the world. After the initial outbreak in the city of Wuhan, Hubei province, COVID-19 is under control in China, with a few small waves caused by imported cases, of which have been stopped in China in 2–4 weeks, with between several cases and hundreds of cases per wave. We have seen clear peak–valley intervals with these small waves. It is crucial to understand why and how China has reached such success because it might help other countries. For COVID-19, we believe that active case finding at the community-level has been the key for China’s achievement. Since the 2003 outbreak of severe acute respiratory syndrome (SARS), health-care reform in China has been focused squarely on community-level capacity building, which compares with countries where community surveillance systems are not ideal.
PEKIN (Reuters) – L’un des potentiels vaccins développés en Chine contre le coronavirus s’est avéré sûr et a déclenché des réponses immunitaires lors des deux premières phases d’essais cliniques sur des volontaires humains, selon une étude publiée jeudi par la revue médicale The Lancet.
While the world is struggling to control COVID-19, China has managed to control the pandemic rapidly and effectively. How was that possible? Talha Burki reports.
The threat of coronavirus should kindle global cooperation, not a new cold war
– Journal acknowledges the country has been widely criticised over Covid-19, but says the world can learn from its disease control successes
– Editorial pushes back on national divisions, calling for ‘global solidarity’ and ‘open collaboration’
– Phase-two trial by team of Chinese scientists ‘induces significant neutralising antibody responses’, paper in peer-reviewed The Lancet reports
– Study out of Britain’s Jenner Institute finds antibodies are still high up to two months after vaccine administered
Le pays compte cinq projets en phase de test, dont quatre ayant recours à des virus inactivés, et a déjà lancé la construction de sites de production.
As of June 8, 2020, the global reported number of COVID-19 cases had reached more than 7 million with over 400 000 deaths. The household transmissibility of the causative pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains unclear. We aimed to estimate the secondary attack rate of SARS-CoV-2 among household and non-household close contacts in Guangzhou, China, using a statistical transmission model.
